Protalix presents PRX-115 Phase 2 gout trial update, expects top-line data in second half of 2027

• Protalix BioTherapeutics is enrolling patients in its Phase 2 RELEASE trial of PRX-115 for uncontrolled gout, with top-line results expected in second-half 2027.
• Revenue rose to $75.6 million for the first nine months of 2026 from $43.6 million a year earlier.
• Net income totaled $26.1 million for the period.
• Cash stood at $48.5 million as of September 30, 2026, with no debt or warrants.
• A $25 million regulatory milestone payment from Chiesi followed expanded Elfabrio dosing options in markets including the EU and UK.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.